Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| ONEG | OneConstruction Group | $4.30 | -$5.96 | -58.09% | 2.7M | $164.2M | $1.48$13.50 |
| TSSI | Tss | $8.64 | -$6.61 | -43.34% | 193.1K | $432.6M | $5.63$31.94 |
| GWH | ESS Tech | $2.70 | -$1.55 | -36.43% | 1.6M | $83.4M | $0.76$13.87 |
| AVXL | Anavex Life Sciences | $3.68 | -$2.01 | -35.30% | 19.4M | $488.7M | $2.86$14.44 |
| ATGL | Alpha Technology Group | $10.00 | -$4.00 | -28.57% | 3.5K | $213.7M | $8.79$57.32 |
| SGBX | Safe & Green | $2.26 | -$0.90 | -28.48% | 3.2M | $1.5M | $1.81$122.88 |
| GAUZ | Gauzy | $2.89 | -$1.13 | -28.06% | 840.5K | $75.3M | $1.98$13.00 |
| SOC | Sable Offshore | $4.26 | -$1.64 | -27.76% | 11.5M | $586.1M | $4.04$35.00 |
| STUB | StubHub | $14.19 | -$4.63 | -24.60% | 602.6K | $6.9B | $12.91$27.89 |
| FOXX | Foxx Development | $2.51 | -$0.74 | -22.81% | 29K | $22.0M | $2.45$11.00 |
Related Articles
Featured Article
Wall Street Thinks This Small-Cap Stock Can Quadruple in Value
David Jagielski|Mar 15, 2023
The company generates no revenue, but it may be worth taking a chance on as it possesses lots of upside.

Is Anavex Life Sciences Stock a Buy Now?
David Jagielski|Feb 23, 2023
A short squeeze could be a possibility if the company can prove that bearish investors are wrong about its business.

This Short-Squeeze Candidate Could Actually Pan Out in the Long Run
George Budwell|Feb 9, 2023
Short-sellers have piled into this clinical-stage biopharma stock.

Anavex Life Sciences Stock Could 5x Before 2025 -- Here's Why
Alex Carchidi|Dec 17, 2022
The biotech will first need to assuage the concerns of experts by elaborating on its latest clinical trial data.

Is Anavex Life Sciences a Buy?
Alex Carchidi|Dec 13, 2022
It still needs to prove that its lead program is as effective as it claims for treating Alzheimer's.

Is Anavex Life Sciences a Smart Stock to Buy Now?
Cory Renauer|Dec 3, 2022
The company's Alzheimer's disease drug just succeeded in a clinical trial. Or did it?

2 Biotech Stocks Set to Go Supernova Soon
George Budwell|Oct 18, 2021
Anavex Life Sciences and Affimed both sport unique drug development platforms that could be worth billions.

3 Biotech Stocks That Have Already Doubled This Year
Cory Renauer|Feb 20, 2020
Can these soaring biotech stocks keep climbing?

Forget Anavex Life Sciences Corp.: These 2 Biotech Stocks Are Better Buys
Cory Renauer|Feb 1, 2017
The tiny biotech's only clinical-stage candidate is a long way from the goal line, making these two biotech stocks far better picks.

Anavex Life Sciences Corp. in 3 Charts
Keith Speights|Dec 6, 2016
These charts show where things stand -- and where they could be headed -- for Alzheimer's disease drug developer Anavex Life Sciences.
